A longitudinal analysis of PEGASYS [peginterferon alfa-2a] on HBV [hepatitis B virus] -specific T cell responses in patients with HBeAg-negative chronic hepatitis B Infection - immunology sub-study of ML18253

Trial Profile

A longitudinal analysis of PEGASYS [peginterferon alfa-2a] on HBV [hepatitis B virus] -specific T cell responses in patients with HBeAg-negative chronic hepatitis B Infection - immunology sub-study of ML18253

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Peginterferon alfa-2a (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 18 Nov 2009 Status changed from active, no longer recruiting to completed as reported by Roche record.
    • 10 Jan 2008 Roche reported as trial sponsor.
    • 24 Apr 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top